Lantheus Medical Imaging, Inc.
331 Treble Cove Road
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.
Mary Anne Heino
President and Chief Executive Officer
Chief Financial Officer and Treasurer
Senior Vice President, Technical Operations
Senior Vice President - Law and Public Policy, General Counsel and Secretary
Sarah Le Roy
Senior Vice President, Human Resources
Senior Vice President, Corporate Development
Cesare Orlandi, M.D.
Chief Medical Officer
Senior Vice President, Research and Pharmaceutical Development
Senior Vice President, Quality
113 articles with Lantheus Medical Imaging, Inc.
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
Lantheus Holdings, Inc., the parent company of Lantheus Medical Imaging, Inc., a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has appointed Robert J. Marshall, Jr. as Chief Financial Officer and Treasurer, effective September 24, 2018.
Lantheus Holdings Reports 2017 Third Quarter Financial Results; Exceeds Third Quarter and Raises Full-Year 2017 Guidance
The Company’s worldwide revenues for the third quarter of 2017 totaled $79.9 million.
Lantheus Medical Imaging To Host Third Quarter 2015 Earnings Conference Call On November 4, 2015 At 4:30 P.M. Eastern Time
Lantheus Medical Imaging's First Phase 3 Study Of Novel PET Cardiac Imaging Agent Flurpiridaz F 18 Data Show Statistically And Clinically Significant Improvements
Lantheus Medical Imaging to Host Third Quarter 2013 Conference Call on November 13, 2013 at 3:00 p.m. Eastern Time
Lantheus Medical Imaging Releases Preliminary Results from Phase 3 Clinical Trial of Flurpiridaz F 18 for the Detection of Coronary Artery Disease
Lantheus Medical Imaging to Present at Imperial Capital Global Opportunities Conference on September 19, 2013
Lantheus Medical Imaging to Host Second Quarter 2013 Conference Call on August 8, 2013 at 4:00 p.m. Eastern Time
Lantheus Medical Imaging to Host First Quarter 2013 Conference Call on May 14, 2013 at 4:00 P.M. Eastern Time
Lantheus Medical Imaging to Proceed With Flurpiridaz F 18 Phase 3 Clinical Program Based on Interim Analysis of Data From First Phase 3 Study
Lantheus Medical Imaging Announces Appointment of Cesare Orlandi, M.D., as New Chief Medical Officer